Not Quite FDARA Add-Ons: Right-To-Try, Patient Experience, Opioid Measures Also Clear US Senate

Senate passage of the FDA user fee package without amendments was enabled by unanimous consent votes on controversial right-to-try legislation that is toned down from its initial version, as well as two other bills.

The US Senate's vote on the House's version of the FDA Reauthorization Act (FDARA) without any amendments was preceded – and enabled – by the quick and easy passage of three pharmaceutical-related bills, including controversial right-to-try legislation that was substantially toned down from its original version.

Had the Senate approved the three bills as amendments to the House's version of FDARA, the amended user fee reauthorization...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet